ZTS
Zoetis Inc.
Is ZTS Halal?
Animal-health medicines are generally permissible, but current debt/assets fails the financial screens.
What You Should Know
Zoetis's March 31, 2026 filing shows debt/assets of 59.69%, liquidity/assets of 12.81% and receivables plus cash/assets of 22.75%; gross interest income is not separately disclosed. Veterinary medicines, vaccines, diagnostics and genetic tests generally support animal health, while ingredients, animal research, contract manufacturing and acquisition activity require qualitative review.
⚠️ Concerns
- •Debt/assets is 59.69% and exceeds the examined FTSE, MSCI and Malaysia limits
- •Veterinary medicines, vaccines and diagnostics require product-ingredient and manufacturing review
- •Animal testing, welfare and clinical research remain material ethical topics
- •The filing reports net interest expense but no separate gross interest-income numerator
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-14.
9,045 / 15,154
1,941 / 15,154
3,447 / 15,154
- Financial
- Fails
- Overall
- Fails
Debt/assets is 59.69%, above the examined FTSE 33.333% limit; liquidity/assets is 12.81% and receivables plus cash/assets is 22.75%, while gross interest income is unavailable.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 59.69%, above the examined MSCI 33.33% total-assets limit; the debt failure is independent of activity classification.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 59.69%, above the examined Malaysia 33% limit; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the debt screen fails independently.
Business-activity disclosure
Zoetis discovers, develops, manufactures and sells veterinary medicines, vaccines, diagnostics, biodevices, genetic tests and precision animal-health services. Animal health is generally permissible, while product ingredients, animal testing, contract manufacturing and human-health activities require continuing scholarly and ethical review.
Limitation: The filing does not allocate revenue by ingredient, excipient, animal-research method, contract-manufacturing customer or other universal prohibited-activity taxonomy.
Purification
Zoetis does not separately disclose gross interest income or prescribe a scholar-approved purification percentage; no fixed rate is inferred.
Inputs, assumptions and primary sources
- Amounts are USD millions from Zoetis's March 31, 2026 Form 10-Q and rounded to the nearest million.
- Long-term debt, net of discount and issuance costs, is $9,045 million; no separate current borrowings are reported and operating leases are excluded.
- Cash and cash equivalents are $1,941 million; no separately identified interest-bearing securities balance is added.
- Accounts receivable, net are $1,506 million and first-quarter revenue is $2,262 million.
- The filing reports net interest expense but does not separately disclose gross interest income, so no income numerator is estimated.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →